Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Total Non-Current Liabilities (2020 - 2025)

Historic Total Non-Current Liabilities for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Q3 2025 value amounting to $477.1 million.

  • Mirum Pharmaceuticals' Total Non-Current Liabilities rose 1046.34% to $477.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $477.1 million, marking a year-over-year increase of 1046.34%. This contributed to the annual value of $442.6 million for FY2024, which is 1230.72% up from last year.
  • Mirum Pharmaceuticals' Total Non-Current Liabilities amounted to $477.1 million in Q3 2025, which was up 1046.34% from $461.6 million recorded in Q2 2025.
  • Mirum Pharmaceuticals' 5-year Total Non-Current Liabilities high stood at $477.1 million for Q3 2025, and its period low was $31.3 million during Q2 2021.
  • Moreover, its 5-year median value for Total Non-Current Liabilities was $365.0 million (2023), whereas its average is $245.7 million.
  • Its Total Non-Current Liabilities has fluctuated over the past 5 years, first crashed by 325.88% in 2022, then surged by 71522.01% in 2024.
  • Mirum Pharmaceuticals' Total Non-Current Liabilities (Quarter) stood at $44.5 million in 2021, then skyrocketed by 58.41% to $70.5 million in 2022, then surged by 458.87% to $394.1 million in 2023, then rose by 12.31% to $442.6 million in 2024, then increased by 7.79% to $477.1 million in 2025.
  • Its Total Non-Current Liabilities stands at $477.1 million for Q3 2025, versus $461.6 million for Q2 2025 and $443.1 million for Q1 2025.